FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601350070> ?p ?o ?g. }

• W2601350070 endingPage "2684" @default.
• W2601350070 startingPage "2684" @default.
• W2601350070 abstract "Abstract BACKGROUND: Few therapeutic options are currently available for patients (pts) with severe aplastic anemia (SAA) refractory to antithymocyte globulin (ATG) plus ciclosporine (CsA) and not eligible for allogeneic stem cell transplantation. It has recently been reported that eltrombopag (ELT), a TPO receptor agonist, is efficient to improve tri-lineage blood counts in this setting. However, real-life use of this drug is still largely unknown. In pts with SAA refractory to ATG, physicians can accede to ELT in France through a compassionate use program. We took advantage of this program to assess the efficacy and safety of ELT in SAA pts. PATIENTS AND METHODS: The French National Reference Center for Aplastic Anemia conducted this study in pts who received ELT for the treatment of SAA. Latest guidelines were used to define disease severity, treatment indication, and response rates (Marsh et al, BJH 2014). The diagnosis of SAA was confirmed by marrow biopsy and Camita criteria for all pts. Pts were eligible if they received at least 2 months of ELT alone or in combination with other treatment in case of relapsed/refractory disease or front-line therapy for pts not eligible to the association of ATG and CsA. Pts were identified through a national e-mailing on behalf of the French reference center for SAA and the French Society of Hematology. All data presented here were collected at the reference date of June 26th, 2016. The study was conducted according to Helsinki's Declaration. RESULTS: Forty-six pts (male, 54%) who received ELT between July 2012 and February 2016 were identified in 17 French centers. Indications for ELT were relapsed/refractory SAA in 35 pts (76%) after 1 (49%), 2 (29%) or 3 (9%) courses of CsA+ATG. Eleven pts considered unfit for ATG also received the drug as first line therapy. The characteristics of the pts according to ELT indications are shown in Table 1. Median age at time of ELT initiation was 61 years [IQR 40 to 70]. 44 pts had idiopathic SAA including 17 (37%) with a detectable PNH clone (median size 7%). Two pts (4%) with dyskeratosis congenita also received ELT. ELT was introduced 17 months [8-50] after the initial diagnosis of SAA and with a median of 6 months [3-14] after the last course of immunosuppressive therapy. The maximal dose was 150 mg/day [100-150] for a median duration time of 6 months [4-12]. At last follow-up 22(48%) pts were still on treatment, 4(9%) pts stopped because of good hematological response, 1(2%) and 15(33%) after limited toxicity and failure to improve hematological status. Before treatment, median neutrophils count was 790/mm3 [500-1215] and pts received a median number of 4 red blood cells packs [2-4] and 3 platelets apheresis units [2-4] every month. Neutrophils counts were 765 [515-1475], 1100 [600-1800], 1200 [670-1915] and 1200/mm3 [757-2300] at 1, 3, 6 months and at last follow-up respectively. The rates of transfusion independence for both red cells and platelets were 7%, 33%, 46% and 46% at 1, 3, 6 months and at last follow-up. In pts achieving transfusion independence, hemoglobin and platelets level improved of 3 gr/dL [1.4, 4.5] and 42 G/L [11, 100], respectively. The rate of transfusion independence was not different among first line and refractory pts (p=0,5). We did not observe any response in the 2 patients with dyskeratosis congenita. No factor associated with hematological response to ELT was identified. Liver toxicity (cytolysis) occurred in 11 pts (1 grade 3 that required withdrawal of the treatment and 10 grade 1 who responded to dose reduction). 2 pts had a grade 2 intestinal toxicity which improved after dose reduction. Other side effects where related to SAA (28% infections, 13% hemorrhages). Bone marrow karyotype analysis after ELT was done in twelve pts (26%) (median time 14 months [5-22] after ELT start). In 10 pts the karyotype was normal, in one, trisomy 8 was identified (already seen at SAA diagnosis), and karyotype was a failure in 1 pt. CONCLUSION: We report here the first real-life multicenter study about the use of ELT in SAA. In a particular severe pts population with no other treatment possibility, we confirm a 40% rate of hematological improvement with transfusion independence. Some of the pts who were not eligible to ATG plus CsA (comorbidities) also received ELT first line with similar response rates. Elderly pts unfit for ATG may thus benefit from this treatment which at the best should be given through prospective clinical trials. Table 1 Table 1. Disclosures Ades: Celgene, Takeda, Novartis, Astex: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Terriou:Novartis: Consultancy; amgen: Consultancy. Peffault de Latour:Alexion: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Amgen: Research Funding." @default.
• W2601350070 created "2017-04-07" @default.
• W2601350070 creator A5007550143 @default.
• W2601350070 creator A5007605254 @default.
• W2601350070 creator A5010632074 @default.
• W2601350070 creator A5010649307 @default.
• W2601350070 creator A5012691135 @default.
• W2601350070 creator A5023982618 @default.
• W2601350070 creator A5024022602 @default.
• W2601350070 creator A5025108931 @default.
• W2601350070 creator A5040576970 @default.
• W2601350070 creator A5041549015 @default.
• W2601350070 creator A5047925131 @default.
• W2601350070 creator A5050597176 @default.
• W2601350070 creator A5052071966 @default.
• W2601350070 creator A5055188307 @default.
• W2601350070 creator A5064103067 @default.
• W2601350070 creator A5064658190 @default.
• W2601350070 creator A5070246382 @default.
• W2601350070 creator A5078516985 @default.
• W2601350070 creator A5080673678 @default.
• W2601350070 creator A5086403776 @default.
• W2601350070 date "2016-12-02" @default.
• W2601350070 modified "2023-10-18" @default.
• W2601350070 title "Nationwide Survey on the Use of Eltrombopag in Patients with Severe Aplastic Anemia: Report on Behalf of the French Reference Center for Aplastic Anemia" @default.
• W2601350070 doi "https://doi.org/10.1182/blood.v128.22.2684.2684" @default.
• W2601350070 hasPublicationYear "2016" @default.
• W2601350070 type Work @default.
• W2601350070 sameAs 2601350070 @default.
• W2601350070 citedByCount "1" @default.
• W2601350070 countsByYear W26013500702018 @default.
• W2601350070 crossrefType "journal-article" @default.
• W2601350070 hasAuthorship W2601350070A5007550143 @default.
• W2601350070 hasAuthorship W2601350070A5007605254 @default.
• W2601350070 hasAuthorship W2601350070A5010632074 @default.
• W2601350070 hasAuthorship W2601350070A5010649307 @default.
• W2601350070 hasAuthorship W2601350070A5012691135 @default.
• W2601350070 hasAuthorship W2601350070A5023982618 @default.
• W2601350070 hasAuthorship W2601350070A5024022602 @default.
• W2601350070 hasAuthorship W2601350070A5025108931 @default.
• W2601350070 hasAuthorship W2601350070A5040576970 @default.
• W2601350070 hasAuthorship W2601350070A5041549015 @default.
• W2601350070 hasAuthorship W2601350070A5047925131 @default.
• W2601350070 hasAuthorship W2601350070A5050597176 @default.
• W2601350070 hasAuthorship W2601350070A5052071966 @default.
• W2601350070 hasAuthorship W2601350070A5055188307 @default.
• W2601350070 hasAuthorship W2601350070A5064103067 @default.
• W2601350070 hasAuthorship W2601350070A5064658190 @default.
• W2601350070 hasAuthorship W2601350070A5070246382 @default.
• W2601350070 hasAuthorship W2601350070A5078516985 @default.
• W2601350070 hasAuthorship W2601350070A5080673678 @default.
• W2601350070 hasAuthorship W2601350070A5086403776 @default.
• W2601350070 hasConcept C126322002 @default.
• W2601350070 hasConcept C141071460 @default.
• W2601350070 hasConcept C187212893 @default.
• W2601350070 hasConcept C2778248108 @default.
• W2601350070 hasConcept C2780007613 @default.
• W2601350070 hasConcept C2780588981 @default.
• W2601350070 hasConcept C2781440808 @default.
• W2601350070 hasConcept C2911091166 @default.
• W2601350070 hasConcept C2993327898 @default.
• W2601350070 hasConcept C71924100 @default.
• W2601350070 hasConcept C89560881 @default.
• W2601350070 hasConcept C90924648 @default.
• W2601350070 hasConceptScore W2601350070C126322002 @default.
• W2601350070 hasConceptScore W2601350070C141071460 @default.
• W2601350070 hasConceptScore W2601350070C187212893 @default.
• W2601350070 hasConceptScore W2601350070C2778248108 @default.
• W2601350070 hasConceptScore W2601350070C2780007613 @default.
• W2601350070 hasConceptScore W2601350070C2780588981 @default.
• W2601350070 hasConceptScore W2601350070C2781440808 @default.
• W2601350070 hasConceptScore W2601350070C2911091166 @default.
• W2601350070 hasConceptScore W2601350070C2993327898 @default.
• W2601350070 hasConceptScore W2601350070C71924100 @default.
• W2601350070 hasConceptScore W2601350070C89560881 @default.
• W2601350070 hasConceptScore W2601350070C90924648 @default.
• W2601350070 hasIssue "22" @default.
• W2601350070 hasLocation W26013500701 @default.
• W2601350070 hasOpenAccess W2601350070 @default.
• W2601350070 hasPrimaryLocation W26013500701 @default.
• W2601350070 hasRelatedWork W2002120878 @default.
• W2601350070 hasRelatedWork W2003938723 @default.
• W2601350070 hasRelatedWork W2047967234 @default.
• W2601350070 hasRelatedWork W2118496982 @default.
• W2601350070 hasRelatedWork W2135977549 @default.
• W2601350070 hasRelatedWork W2409957712 @default.
• W2601350070 hasRelatedWork W2439875401 @default.
• W2601350070 hasRelatedWork W2901330354 @default.
• W2601350070 hasRelatedWork W3203700472 @default.
• W2601350070 hasRelatedWork W2525756941 @default.
• W2601350070 hasVolume "128" @default.
• W2601350070 isParatext "false" @default.
• W2601350070 isRetracted "false" @default.
• W2601350070 magId "2601350070" @default.
• W2601350070 workType "article" @default.